These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26037945)

  • 1. Behavioral impairments and serotonin reductions in rats after chronic L-dopa.
    Stansley BJ; Yamamoto BK
    Psychopharmacology (Berl); 2015 Sep; 232(17):3203-13. PubMed ID: 26037945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus.
    Stansley BJ; Yamamoto BK
    J Pharmacol Exp Ther; 2014 Nov; 351(2):440-7. PubMed ID: 25212217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
    Eskow Jaunarajs KL; George JA; Bishop C
    Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain.
    Inoue T; Tsuchiya K; Koyama T
    Pharmacol Biochem Behav; 1994 Dec; 49(4):911-20. PubMed ID: 7886107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats.
    Borah A; Mohanakumar KP
    Cell Mol Neurobiol; 2007 Dec; 27(8):985-96. PubMed ID: 17934805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce expression of fear and depression-like behavior.
    McDevitt RA; Hiroi R; Mackenzie SM; Robin NC; Cohn A; Kim JJ; Neumaier JF
    Biol Psychiatry; 2011 Apr; 69(8):780-7. PubMed ID: 21353664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
    Eskow Jaunarajs KL; Dupre KB; Ostock CY; Button T; Deak T; Bishop C
    Behav Pharmacol; 2010 Oct; 21(7):627-37. PubMed ID: 20838211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
    Miguelez C; Navailles S; Delaville C; Marquis L; Lagière M; Benazzouz A; Ugedo L; De Deurwaerdère P
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1297-309. PubMed ID: 27234917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
    Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
    BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
    Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
    Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of conditioned fear stress on monoaminergic systems in the rat brain].
    Inoue T
    Hokkaido Igaku Zasshi; 1993 May; 68(3):377-90. PubMed ID: 7686527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.